Search by Drug Name or NDC

NDC 00409-1703-01 BORTEZOMIB 2.5 mg/1 Details

BORTEZOMIB 2.5 mg/1

BORTEZOMIB is a INTRAVENOUS; SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Hospira, Inc.. The primary component is BORTEZOMIB.

MedlinePlus Drug Summary

Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow). Bortezomib is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system). Bortezomib is in a class of medications called antineoplastic agents. It works by killing cancer cells.

Related Packages: 00409-1703-01
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Bortezomib

Product Information

NDC	00409-1703
Product ID	0409-1703_e7c31651-e301-43f9-bc81-e0fd5dcb828c
Associated GPIs	21536015002113
GCN Sequence Number	081369
GCN Sequence Number Description	bortezomib VIAL 2.5 MG INJECTION
HIC3	V1Q
HIC3 Description	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS
GCN	48454
HICL Sequence Number	025202
HICL Sequence Number Description	BORTEZOMIB
Brand/Generic	Generic
Proprietary Name	BORTEZOMIB
Proprietary Name Suffix	n/a
Non-Proprietary Name	BORTEZOMIB
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route	INTRAVENOUS; SUBCUTANEOUS
Active Ingredient Strength	2.5
Active Ingredient Units	mg/1
Substance Name	BORTEZOMIB
Labeler Name	Hospira, Inc.
Pharmaceutical Class	Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA209191
Listing Certified Through	2024-12-31

Package

NDC 00409-1703-01 (00409170301)

Pricing Information	N/A
NDC Package Code	0409-1703-01
Billing NDC	00409170301
Package	1 VIAL, SINGLE-DOSE in 1 CARTON (0409-1703-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
Marketing Start Date	2022-05-16
NDC Exclude Flag	N